Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist (IMAGE)
Caption
Notably, in January of this year, Insilico announced the nomination of another GIPR antagonist, ISM0676, which demonstrated up to a 31.3% weight loss when used in combination with Semaglutide in humanized mouse models. In comparison, the newly nominated PCC maintains robust weight-loss efficacy while delivering further improvements in pharmacokinetic and safety profiles, while retaining its favorable drug-like properties.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content